Fig. 5: Inhibition of TGF-β or BMP signaling delays the decrease in body weight of MOB1A/B-depleted mice. | Cell Death & Disease

Fig. 5: Inhibition of TGF-β or BMP signaling delays the decrease in body weight of MOB1A/B-depleted mice.

From: Depletion of MOB1A/B causes intestinal epithelial degeneration by suppressing Wnt activity and activating BMP/TGF-β signaling

Fig. 5

a Percent changes in body weight of vehicle-treated wild type and vehicle- or inhibitor-treated MOB1A/B iKO mice after tamoxifen treatment. Vehicle-treated wild-type mice, n = 6; vehicle-treated MOB1A/B iKO mice, n = 8; dibenzazepine (DBZ)-treated MOB1A/B iKO mice, n = 6; pyrvinium-treated MOB1A/B iKO mice, n = 6; LDN-treated MOB1A/B iKO mice, n = 7; SB-treated MOB1A/B iKO mice, n = 6; combination treatment with LDN and SB in MOB1A/B iKO mice, n = 6. b Western blot analysis of IECs isolated 6 days after treatment with tamoxifen and indicated inhibitors in control and MOB1A/B iKO mice. c Quantification of protein levels for pSmad1/5 and pSmad2 from (b). d Quantitative results showing expression levels of Bmp2 and Tgfbr2 mRNA isolated from IECs in (b). Data are presented as the mean ± SEM. **P < 0.01, ***P < 0.001

Back to article page